Skip to main content
. 2022 Nov 30;14(12):2668. doi: 10.3390/pharmaceutics14122668

Table 3.

Levels of cyclin D1 and p-38 MAPK of MTX-MNMs and PIP-NMs/MTX-MNMs -treated groups as compared to the control group. Data represented as mean ± SD (n = 7).

Group Cyclin D1 (ng/mL) p-38 MAPK (ng/mL)
Control 8.4 ± 0.21 16.6 ± 1.17
MTX-MNMs 2.2 ± 0.16 4.7 ± 0.08
PIP-NMs/MTX-MNMs 2.4 ± 0.12 3.1 ± 0.2